WAJAN ALQATHANİN, MOHAMMED KANAN, KHULUD GHAZWANİ, SARAH ALSAGGAF, RENAD A ALSHEHRİ, WASAYEF ALQHTANİ, ABEER ALAMRİ, ALYA ALHİDER, WAJİN ALRUWİLİ, SARAH SAEED, BANAN ALSUFAYAN, AFNAN ALGARNİ, BANH ALGHADYAH, AMJAD S ALQARNİ, NAİF AL RASHEEDİ
ENT Updates - 2025;15(2):37-54
Ciproloxacin, a luoroquinolone antibiotic, plays a crucial role in treating otitis externa, which is a common inlammatory disorder of the outer ear canal. This review examines the effectiveness and safety of ciproloxacin in managing otitis externa, with a focus on its pharmacological properties, antibacterial effects, and outcomes. This review highlights the potent activity of ciproloxacin against the primary pathogens Pseudomonas aeruginosa and Staphylococcus aureus and its ability to penetrate the auditory canal, making it ideal for treating ear infections. The use of oral ciproloxacin in severe cases, particularly in malignant otitis externa, is also discussed. This review explores the beneits and drawbacks of topical and oral ciproloxacin formulations and the rationale for combining these routes in complex cases. Special attention should be given to prescribing ciproloxacin to vulnerable populations, such as children, the elderly, and pregnant women. The increasing prevalence of ciproloxacin-resistant bacteria and the importance of antimicrobial stewardship programs in combating resistance are emphasized. This review addresses drug interactions and monitoring strategies. Future directions in otitis externa treatment are discussed, including the development of safer quinolones, advancements in targeted drug delivery systems, and progress in diagnostic tools for antibiotic selection. This review underscores the signiicance of ciproloxacin in managing otitis externa while highlighting the need for judicious use and research to optimize outcomes and mitigate resistance risk.
